Loading...
•
Dec 31, 2020
Onconova Q4 2020 Earnings Report
Reported financial results for full year 2020 and provided a business update.
Key Takeaways
Onconova Therapeutics reported its full year 2020 financial results, with a net loss of $25.2 million and cash and cash equivalents of $19.0 million as of December 31, 2020. The company is advancing its lead product ON 123300 into clinical trials and supporting investigator-initiated studies with oral rigosertib.
Submitted an Investigational New Drug application to the FDA for a Phase 1 study in advanced cancers.
Received clearance from the FDA to begin the Phase 1 study and received IRB approval at the first site.
Partner HanX Pharmaceuticals continues enrolling patients in a Phase 1 dose-escalation study with ON 123300 in China.
Supporting investigator-initiated studies exploring the use of oral rigosertib for cancers driven by mutation of the RAS gene.
Forward Guidance
The Company expects that its cash and cash equivalents as of February 28, 2021 will be sufficient to fund ongoing clinical trials and business operations for more than eighteen months.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...